IAH0968 has shown the same binding properties to HER2 as trastuzumab and enhanced binding affinity to FcγRIIIa allotypes, improved the activity of ADCC and superior anti-tumor efficacy (on-line Supplementary Table S1, Supplementary Figures S1, S2). This evidence concerns the gene ERBB2 and neoplasm.